# DREAMM-10 (NCT06679101)

> A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06679101
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: GlaxoSmithKline
- Conditions: Multiple Myeloma; Newly Diagnosed Multiple Myeloma
- Interventions: Belantamab mafodotin; Lenalidomide; Dexamethasone; Daratumumab
- Enrollment: 520
- Primary outcome: PFS
- Primary outcome: Number of Participants Achieving MRD Negative Status

## Commentary we found

- YouTube: 8
- Podcasts: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dreamm-10-nct06679101

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06679101", "email": "<work email>"}; the inbox owner confirms by the emailed link.